Claim 55% Off TipRanks
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Discover top-performing stock ideas and upgrade to a portfolio of market leaders with Smart Investor Picks
An announcement from China Resources Pharmaceutical Group Ltd. ( (HK:3320) ) is now available.
Dong-E-E-Jiao, a key subsidiary of China Resources Pharmaceutical Group, reported modest balance sheet expansion for 2025, with total assets rising 2.18% and net assets attributable to shareholders edging up 0.20%. The company strengthened profitability, lifting revenue 8.83% to RMB6.70 billion and increasing net profit attributable to shareholders by 11.66%, while core earnings excluding extraordinary items grew 13.62% and earnings per share climbed to RMB2.70.
Despite the solid earnings performance, net cash flow from operating activities declined 19.70%, signaling potential pressure on cash generation even as returns on net assets improved to 16.66%. The board of Dong-E-E-Jiao has proposed a cash dividend of RMB14.31 per 10 shares, pending shareholder approval, which would deliver a tangible payout to investors and support China Resources Pharmaceutical Group’s income stream from its consolidated traditional Chinese medicine business.
The most recent analyst rating on (HK:3320) stock is a Hold with a HK$5.00 price target. To see the full list of analyst forecasts on China Resources Pharmaceutical Group Ltd. stock, see the HK:3320 Stock Forecast page.
More about China Resources Pharmaceutical Group Ltd.
China Resources Pharmaceutical Group Limited is a Hong Kong–incorporated pharmaceutical conglomerate with a controlling stake in Dong-E-E-Jiao Co., Ltd., a Shenzhen-listed traditional Chinese medicine producer best known for its Ejiao-based health products. Through direct and indirect holdings totaling about 23.50%, the group consolidates Dong-E-E-Jiao as a subsidiary, integrating its results into the wider pharmaceutical portfolio focused on the Chinese healthcare market.
Average Trading Volume: 9,607,392
Technical Sentiment Signal: Sell
Current Market Cap: HK$29.28B
See more data about 3320 stock on TipRanks’ Stock Analysis page.